跳至主要内容
临床试验/NCT05991986
NCT05991986尚未招募不适用

Production of Patient Autologous Induced Pluripotent Stem Cell-derived Retinal Cells for Age-related Macular Degeneration

Zhongshan Ophthalmic Center, Sun Yat-sen University0 个研究点目标入组 10 人开始时间: 2025年8月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
10
主要终点
somatic cell collection

研究概览

简要总结

This project intends to collect participant somatic cells to prepare autologous induced pluripotent stem cell-derived retinal cells for future cell therapy of age-related macular degeneration patient.

详细描述

One or more types of somatic cells will be collected from every participant by collecting approximately 100~500 ml of midstream urine, 20~30 ml of peripheral blood, skin biopsies (3mm), conjunctiva biopsies (5mm×5mm), etc. Then, these somatic cells will be used to prepare patient autologous induced pluripotent stem cell-derived retinal cells for the cell therapy of age-related macular degeneration patient.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Other

入排标准

年龄范围
55 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Aged 55-80 years;
  • Clinical diagnosis is consistent with the definition of advanced age-related macular degeneration;
  • The BCVA of the target eye will be lower than 20/200;
  • 8.00 D < refraction < +8.00 D, 21 mm < anteroposterior axis≤ 28 mm;
  • Voluntary as test subjects, informed consent, regular follow-up on time;
  • Voluntary as test subjects to join the associated clinical research on autologous iPSC-derived retinal cell therapy for AMD (ethical approval and informed consent documents will be applied and signed separately);

排除标准

  • Macular atrophy caused by other diseases in addition to AMD;
  • Malignant tumor and history of malignancy;
  • Any immune deficiency;
  • Lens opacities (affecting the central vision), glaucoma, uveitis, retinal detachment, inherited retinal dystrophy, optic neuropathy, and other ocular histories;
  • Other intraocular surgery histories besides cataract surgery;
  • Severe heart failure or the left ventricular ejection fraction <35% in the previous 6 months;
  • Dialysis or eGFR <20ml/min/1.73m2;
  • Urine protein/urine creatinine ratio ≥1g/g;
  • Creatinine or albumin/urine creatinine ratio ≥600mg/g;
  • Chronic liver disease with ALT three times over the upper limit of normal value;
  • Combined with severe systemic diseases, such as heart failure, liver disease, COPD, etc.
  • Combined with severe infectious diseases, such as HIV, HBV, HCV, syphilis, etc.
  • HCV-RNA positive, HBV-DNA >103 IU/ml, or TB, etc., during the infectious period;
  • Use anticoagulant, or the platelet function is still not restored to normal after stopping antiplatelet drugs for 10 days;
  • Abnormal blood coagulation function or other laboratory tests;
  • Use glucocorticoids, immunosuppressive drugs, or antipsychotic drugs in the previous 3 months;
  • Use antipsychotic drugs in the previous 3 months, such as antidepressants drugs, antimanic drugs, etc.
  • Allergy to tacrolimus or other macrolides;
  • A history of addiction to alcoholism or prohibited drugs;
  • Be participating in other intervention clinical trials or receiving other study medications;
  • Informed refusal;
  • Some other situations which might increase the risks of the subjects or interfere with clinical trials, such as mental disorders, cognitive dysfunction, etc.

结局指标

主要结局

somatic cell collection

时间窗: 2023.8.1~2026.7.31

somatic cell collection

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Xiufeng Zhong

Prof

Zhongshan Ophthalmic Center, Sun Yat-sen University

相似试验